Verbeek Rutger, Hovingh G Kees, Boekholdt S Matthijs
aDepartment of Vascular MedicinebDepartment of Cardiology, Academic Medical Center, Amsterdam, the Netherlands.
Curr Opin Lipidol. 2015 Dec;26(6):502-10. doi: 10.1097/MOL.0000000000000237.
In this review, we summarize the evidence with regard to the rationale of using nonhigh density lipoprotein cholesterol (non-HDL-C) as a cardiovascular disease (CVD) risk factor, in relation to low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB).
In the 2015 National Lipid Association Annual Summary non-HDL-C is considered a coprimary target, apart from LDL-C. The other data published in the last 18 months about non-HDL-C support all the previous published data. There are no recent findings, which we deem to cause a change of the current opinion about non-HDL-C as a predictor for CVD.
The existing evidence supports the claim that non-HDL-C is superior to LDL-C in CVD risk estimation.
在本综述中，我们总结了有关将非高密度脂蛋白胆固醇（non-HDL-C）作为心血管疾病（CVD）风险因素的理论依据的证据，涉及低密度脂蛋白胆固醇（LDL-C）和载脂蛋白B（apoB）。
在2015年美国国家脂质协会年度总结中，除LDL-C外，non-HDL-C被视为共同主要目标。过去18个月中发表的其他有关non-HDL-C的数据支持了之前发表的所有数据。近期没有我们认为会导致改变当前对non-HDL-C作为CVD预测指标看法的发现。
现有证据支持在CVD风险评估中non-HDL-C优于LDL-C这一观点。
